Tenofovir alafenamide (TAF) has been approved to prevent HBV reactivation for HBsAg-positive cancer patients receiving chemotherapy. However, the real-world effectiveness and safety of TAF for cancer patients was lacing. Therefore, we conduct a prospective single arm study to evaluate the efficacy and safety of TAF as a prophylactic antiviral agent for HBsAg-positive cancer patients receiving chemotherapy.
No linked publications found in PubMed
Inclusion Criteria: * Adult patients (age ≥20) with positive HBsAg who are prepared to receive systemic chemotherapy * The presence of HBs antigen should be confirmed within recent two years * The patients who could receive systemic chemotherapy in 4 weeks Exclusion Criteria: * Patients with poor performance status (Zubrod-ECOG ≥ 2 or Karnofsky score ≤ 70) * Patients with cirrhosis * Patients had eGFR lower than 15 ml/min/1.73m2 and didn't receive dialysis * Patients had exposure to any NUC or interferon within 6 months before chemotherapy * Patients were co-infected with HCV or HIV * Allergy history to any tenofovir-based medication * Pregnant woman * Unable to sign inform consent